The proliferation of observational literature on the topic of high-flow nasal cannula (HFNC) as a therapy for acute viral bronchiolitis is nothing short of remarkable. A brief PubMed search reveals a ratio of observational studies to randomized trials of at least 10 to 1 in the past 3 years alone. This proliferation suggests that, right or wrong, we have embraced the widespread use of HFNC clinically. This ratio also hints at a bigger problem, which is that we have moved on to answering somewhat peripheral questions about the therapy prior to answering the most important questions about clinical utility.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Ralston SL. High-Flow Nasal Cannula Therapy for Pediatric Patients With Bronchiolitis: Time to Put the Horse Back in the Barn. JAMA Pediatr. Published online March 23, 2020. doi:10.1001/jamapediatrics.2020.0040
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: